- Details
- Alicia Morgans hosts a multidisciplinary discussion with David Morris and Benjamin Garmezy focusing on the treatment of newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Morris highlights the increasing trend of referring patients with high-volume Gleason 8 disease and metastatic cancer to tertiary care centers. He emphasizes the importance of early discussions about intens...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the amended AUA guidelines for advanced prostate cancer, focusing on triplet therapy for metastatic hormone-sensitive prostate cancer (mHSPC) and non-metastatic castrate-resistant prostate cancer (M0 CRPC). They delve into the role of triplet therapy in mHSPC, examining its benefits across disease volume and risk subgroups, as evidenced by the ARASENS and PE...
|
- Details
- Dingwei Ye introduces a conversation with Alicia Morgans, featuring insights from Professor Yao Zhu, Deputy Executive Director of Urology Surgery at Fudan University Shanghai Cancer Center, on the recent findings from the ARASENS study in the Chinese population. Professor Zhu shares that the study included 202 Chinese patients, about one-seventh of the total, revealing significant efficacy of daro...
|
- Details
- Alicia Morgans speaks with Yong YANG about prostate cancer in China, focusing on the ARASENS Phase 3 Clinical Trial. Professor YANG reveals that prostate cancer incidence in China is about 12 per 10,000, with a lower five-year survival rate than in the USA, largely due to late diagnoses. Approximately 60% of patients initially presented with metastasis. Treatment follows international guidelines a...
|
- Details
- Andrea hosts Jessica Hawley and Aleksandar Obradovic to discuss their study, published in Cancer Cell, which explores the effects of combining Anti-PD-1 immunotherapy with Androgen Deprivation Therapy (ADT) in metastatic castration-sensitive prostate cancer. The research, part of the PRIME-CUT Study, used advanced techniques like single-cell RNA sequencing and quantitative immunofluorescence to an...
|
- Details
- Gerhardt Attard discusses advancing the treatment of advanced hormone-sensitive prostate cancer through biological research. Dr. Attard's work focuses on two main areas: analyzing tumor samples from clinical trials to understand the biology driving cancer aggressiveness and identifying new therapeutic targets. He emphasizes the need for prognostic tests to tailor treatments, especially considering...
|
- Details
- Zach Klaassen hosts a discussion with Fred Saad about the ARASENS data and its transformative impact on prostate cancer treatment. This conversation primarily explores the correlation between a rapid, deep, and durable PSA response and excellent patient outcomes. Dr. Saad underlines the biological significance of a decline in PSA, noting how patients who achieve undetectable PSA levels significant...
|
- Details
- Neeraj Agarwal articulates his vision for the future of treating metastatic castration-sensitive prostate cancer (CSPC). Agarwal delves into the remarkable therapeutic advancements in the past decade, notably, the shift to doublet and triplet therapies. Despite these developments, he draws attention to the underutilization of such treatments in real-world settings due to various barriers. Primaril...
|
- Details
- Alicia Morgans engages with Fred Saad to discuss a network meta-analysis concerning treatments for patients with metastatic hormone-sensitive prostate cancer. They explore the controversies surrounding the most effective treatment for newly diagnosed disease, considering factors like disease volume and whether it's recurrent or de novo. Dr. Saad explains the diminishing role of ADT alone, emphasiz...
|
- Details
- Alicia Morgans interviews Ben Maughan focusing on a published network meta-analysis involving 11 randomized control trials for patients treated for metastatic hormone-sensitive prostate cancer. The analysis stirred significant debate on Twitter and sought to establish whether triplet therapy was superior to other approaches like ADT plus docetaxel and ADT plus an AR-targeted therapy. Dr. Maughan e...
|
